This positive effect of GLP-1RA therapy on insulin secretion was previously demonstrated for liraglutide in a prospective study enrolling patients with type 2 diabetes and obesity [26], in which 14 weeks of liraglutide therapy led to the improvement of glucose control and insulin sensitivity and resistance parameters. The gene discussed is INS; the disease is obesity disorder.